Evidence map›Paper›PMID 39133652›Full record

ArticleJCI insight2024

Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma.

Santhoshkumar Sundaramoorthy, Daniele Filippo Colombo, Rajendran Sanalkumar, Liliane Broye, Katia Balmas Bourloud, Gaylor Boulay, Luisa Cironi, Ivan Stamenkovic, Raffaele Renella, Fabien Kuttler and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Santhoshkumar SundaramoorthyExperimental Pathology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Daniele Filippo ColomboInfectious Diseases Biomarkers, Janssen Research and Development, Beerse, Belgium.
Rajendran SanalkumarExperimental Pathology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Liliane BroyeExperimental Pathology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Katia Balmas BourloudDepartment Woman-Mother-Child, Division of Pediatrics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Gaylor BoulayDepartment of Pathology and Cancer Center, Massachusetts General Hospital and Harvard Medical School.
Luisa CironiExperimental Pathology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Ivan StamenkovicExperimental Pathology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Raffaele RenellaDepartment Woman-Mother-Child, Division of Pediatrics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Fabien KuttlerBiomolecular Screening Facility, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Gerardo TurcattiBiomolecular Screening Facility, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Miguel N RiveraDepartment of Pathology and Cancer Center, Massachusetts General Hospital and Harvard Medical School.
Annick Mühlethaler-MottetDepartment Woman-Mother-Child, Division of Pediatrics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Anaïs Flore BardetBiotechnology and Cell Signaling (BSC), CNRS UMR7242, University of Strasbourg, Illkirch, France.
Nicolò RiggiExperimental Pathology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of targeted therapies offers new hope for patients affected by incurable cancer. However, multiple challenges persist, notably in controlling tumor cell plasticity in patients with refractory and metastatic illness. Neuroblastoma (NB) is an aggressive pediatric malignancy originating from defective differentiation of neural crest-derived progenitors with oncogenic activity due to genetic and epigenetic alterations and remains a clinical challenge for high-risk patients. To identify critical genes driving NB aggressiveness, we performed combined chromatin and transcriptome analyses on matched patient-derived xenografts (PDXs), spheroids, and differentiated adherent cultures derived from metastatic MYCN nonamplified tumors. Bone marrow kinase on chromosome X (BMX) was identified among the most differentially regulated genes in PDXs and spheroids versus adherent models. BMX expression correlated with high tumor stage and poor patient survival and was crucial to the maintenance of the self-renewal and tumorigenic potential of NB spheroids. Moreover, BMX expression positively correlated with the mesenchymal NB cell phenotype, previously associated with increased chemoresistance. Finally, BMX inhibitors readily reversed this cellular state, increased the sensitivity of NB spheroids toward chemotherapy, and partially reduced tumor growth in a preclinical NB model. Altogether, our study identifies BMX as a promising innovative therapeutic target for patients with high-risk MYCN nonamplified NB.

Indexed as

NeuroblastomaN-Myc Proto-Oncogene ProteinSpheroids, CellularAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceProtein-Tyrosine KinasesXenograft Model Antitumor AssaysBMX protein, humanMYCN protein, humanN-Myc Proto-Oncogene ProteinProtein-Tyrosine KinasesCancerEpigeneticsOncogenesTherapeutics

Identifiers

PMID39133652
PMCPMC11383371

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.